We rank companies based on fund manager, research analyst and news sentiment
BCLI stock icon

Brainstorm Cell Therapeutics Inc.


About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Employees: 29

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $928K [Q3] → $1.02M (+$91.3K) [Q4]

2.71% less ownership

Funds ownership: 10.65% [Q3] → 7.93% (-2.71%) [Q4]

17% less funds holding

Funds holding: 53 [Q3] → 44 (-9) [Q4]

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

56% less call options, than puts

Call options by funds: $20.7K | Put options by funds: $47.5K

Research analyst outlook

We haven’t received any recent analyst ratings for BCLI.

Financial journalist opinion

Based on 5 articles about BCLI published over the past 30 days